Phase 4 Gastro-oesophageal Reflux Disease Trial, Recruiting NCT06564246 Sponsor: Tanta University Condition: Gastro-oesophageal Reflux Disease
Back to Gord

Phase 4 Gastro-oesophageal Reflux Disease Trial, Recruiting

NCT06564246
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between the ages of 17 and 60 years old
  • People of any gender
  • People who score 8 or higher on a standard GERD symptom questionnaire (called the GERD-Q), which is used to confirm a diagnosis of acid reflux disease

Who may not be able to join:

  • People who have a history of digestive tract diseases, previous stomach or small intestine surgery, inflammatory bowel disease, or a condition called Barrett's esophagus (a change in the lining of the food pipe)
  • People who have had or currently have a condition called Zollinger-Ellison syndrome, or other conditions that cause the stomach to produce too much acid, including stomach or duodenal ulcers
  • People who have had all or part of their stomach surgically removed, or who have a condition called esophageal achalasia (where the food pipe has trouble moving food into the stomach)
  • People who have had COVID-19
  • People with serious heart, lung, hormonal, metabolic, or mental health conditions
  • People who are pregnant or breastfeeding
  • People whose liver test results are above certain levels — specifically, total bilirubin at or above 1.2 mg/dl or ALT above 100 IU/l (confirm with trial site)
  • People with significant kidney problems, where kidney function falls below a certain level (confirm with trial site)
  • People currently taking the medications atazanavir sulphate, nelfinavir, or rilpivirine hydrochloride, due to the risk of these drugs interacting with the trial treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Aya Hany Abdel Aziz, Master degree student at faculty of pharmacy - Tanta university

Phone: +201144818823

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Tanta University
Registry
ClinicalTrials.gov
Start date
18 September 2024
Est. completion
1 August 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

change in the measured biomarker

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov